Skip to content
value.today
Cellectar Biosciences, Inc. logo

Cellectar Biosciences, Inc.

CLRB
$12 Mmarket cap on Oct 30, 2026-65.0% since Jan 2024
Compare
World rank
#25,522
Revenue
—
For year ending December-2025
Net income
$-22 M
SEC filing
Employees
—

Cellectar Biosciences, Inc. in brief

Cellectar Biosciences, Inc. is a listed company in the Biotechnology industry, based in Florham Park, New Jersey, USA. Its market value was $12 M on 30 October 2026, which makes it the 25,522nd largest listed company in the world and the 4,258th largest in the USA on this site. James V. Caruso is its chief executive. Its shares trade under the symbol CLRB (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Cellectar Biosciences, Inc.

We are a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid ether drug conjugate ™ (PDC™) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. We believe that our PDC platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments, and we plan to develop PDCs both independently and through research and development collaborations.

From the company's annual report filed with the US SEC: read the report

Cellectar Biosciences, Inc. timeline

3 events, 2004–2014
  1. 2004
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2005
  4. ✎
    Renamed Novelos Therapeutics, Inc.
    Formerly Common Horizons Inc.
  5. 2014
  6. ✎
    Renamed Cellectar Biosciences, Inc.
    Formerly Novelos Therapeutics, Inc..

Events of Cellectar Biosciences, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$26 M$52 M$79 M$105 M2020202120222023202420252026

World rank over time

▼ down 899 places since 2020
2020-01-01: #24631#24,63120202021-01-01: #18294#18,29420212022-01-07: #27504#27,50420222022-12-25: #30392#30,39220222023-07-30: #29649#29,64920232024-01-05: #26534#26,53420242026-03-08: #12605#12,60520262026-08-01: #21676#21,67620262026-10-14: #25309#25,30920262026-10-30: #25530#25,5302026

Rank in USA: #4,451 (Jan 2020) · #3,709 (Jan 2021) · #5,002 (Jan 2022) · #5,407 (Dec 2022) · #5,204 (Jul 2023) · #4,206 (Jan 2024) · #2,360 (Mar 2026) · #3,938 (Aug 2026) · #4,184 (Oct 2026) · #4,259 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
1.4×
Free cash flow yield
-188.8%
Net margin
—
Operating margin
—
Return on equity
-255.2%
Liabilities / assets
33.8%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-13M—FY18Fiscal year ending Dec 2019: revenue —, net income $-14M—FY19Fiscal year ending Dec 2020: revenue —, net income $-15M—FY20Fiscal year ending Dec 2021: revenue —, net income $-24M—FY21Fiscal year ending Dec 2022: revenue —, net income $-32M—FY22Fiscal year ending Dec 2023: revenue —, net income $-43M—FY23Fiscal year ending Dec 2024: revenue —, net income $-45M—FY24Fiscal year ending Dec 2025: revenue —, net income $-22M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-23M$-22M—
Dec 2024——$-52M$-45M—
Dec 2023——$-39M$-43M—
Dec 2022——$-29M$-32M—
Dec 2021——$-24M$-24M—
Dec 2020——$-15M$-15M—
Dec 2019——$-14M$-14M—
Dec 2018——$-13M$-13M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-23M$0M$-23M$-8.35—
Dec 2024$-48M$0M$-48M$-41.89—
Dec 2023$-32M$1M$-33M$-3.50—
Dec 2022$-25M$0M$-25M$-4.51—
Dec 2021$-23M$0M$-23M$-4.35—
Dec 2020$-14M$0M$-14M$-1.84—
Dec 2019$-12M$0M$-12M$-1.84—
Dec 2018$-11M$0M$-12M$-5.23—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-2M—Dec ’24Three months to Mar 2025: revenue —, net income $-7M—Mar ’25Three months to Jun 2025: revenue —, net income $-5M—Jun ’25Three months to Sep 2025: revenue —, net income $-4M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-5M—Dec ’25Three months to Mar 2026: revenue —, net income $-6M—Mar ’26Three months to Jun 2026: revenue —, net income $-7M—Jun ’26Three months to Sep 2026: revenue —, net income $-8M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-8M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Cellectar Biosciences, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-23 M
Net income
$-22 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$15 M
Total liabilities
$5 M
Total equity
$9 M

As of December-2025

Top 28 institutional investors in Cellectar Biosciences, Inc.#

As of Sep 30, 2026
28 institutions held 4.6 M shares (about 46.3% of the shares outstanding) on Sep 30, 2026. The ten largest hold 42.6%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Cellectar Biosciences, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Empery Asset Management, LP955,118+765,513 (+403.74%)9.51%$2 MNov 16, 2026
2Stonepine Capital Management, LLC749,028+644,478 (+616.43%)7.46%$1 MNov 13, 2026
3Caligan Partners LP469,9980 (0.00%)4.68%$1 MNov 16, 2026
4Janus Henderson Group Ltd.465,999—4.64%$1 MNov 16, 2026
5Stempoint Capital LP447,360+92,422 (+26.04%)4.46%$1 MNov 16, 2026
6Vanguard Capital Management LLC310,898-16,469 (-5.03%)3.10%$1 MNov 13, 2026
7Bleichroeder LP288,6790 (0.00%)2.88%$1 MNov 13, 2026
8Balyasny Asset Management L.P.220,0000 (0.00%)2.19%$0 MNov 16, 2026
9Nantahala Capital Management, LLC219,998-219,998 (-50.00%)2.19%$0 MNov 13, 2026
10Silverarc Capital Management, LLC151,118-170,610 (-53.03%)1.51%$0 MNov 12, 2026
11Boothbay Fund Management, LLC85,0690 (0.00%)0.85%$0 MNov 16, 2026
12Diadema Partners LP71,382-66,959 (-48.40%)0.71%$0 MNov 16, 2026
13Geode Capital Management, LLC69,301+15,950 (+29.90%)0.69%$0 MNov 6, 2026
14Vanguard Fiduciary Trust Co46,2200 (0.00%)0.46%$0 MNov 13, 2026
15Sequoia Financial Advisors, LLC32,050+10,200 (+46.68%)0.32%$0 MNov 13, 2026
16Persistent Asset Partners Ltd20,528-72,455 (-77.92%)0.20%$0 MNov 13, 2026
17Acadian Asset Management LLC16,5770 (0.00%)0.17%$0 MNov 9, 2026
18Northern Trust Corp14,8390 (0.00%)0.15%$0 MNov 16, 2026
19BlackRock, Inc.4,7350 (0.00%)0.05%$0 MNov 13, 2026
20UBS Group AG3,218+125 (+4.04%)0.03%$0 MNov 10, 2026
21Nuveen, LLC1,197New0.01%$0 MNov 10, 2026
22Morgan Stanley500-10 (-1.96%)0.01%$0 MNov 13, 2026
23TD Waterhouse Canada Inc.630 (0.00%)0.00%$0 MOct 16, 2026
24Osaic Holdings, Inc.70 (0.00%)0.00%$0 MNov 12, 2026
25SBI Securities Co., Ltd.6-5 (-45.45%)0.00%$0 MOct 22, 2026
Show all 28: investors 26 to 28
Institutional investors 26 to 28 in Cellectar Biosciences, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Key Financial Inc3New0.00%$0 MNov 2, 2026
27FMR LLC2New0.00%$0 MNov 10, 2026
28Danske Bank A/s20 (0.00%)0.00%$0 MNov 9, 2026

Mutual funds holding Cellectar Biosciences, Inc.#

7 funds hold shares worth $1 M (about 3.6% of the company). Since their previous reports 4 added shares and 0 sold, buying $1 M net.
Mutual funds holding Cellectar Biosciences, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.184,145$1 M1.8%<0.01%+263%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.143,222$0 M1.4%<0.01%+360%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC26,977$0 M0.27%<0.01%+27%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC5,641$0 M0.06%<0.01%+21%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC2,064$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC200$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC1$0 M<0.01%<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 7 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Cellectar Biosciences, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$25 K
2 purchases, 2 insiders
Sold, 12 months
$733
1 sale, 1 insider
Net, 12 months
$24 K
open market only
Insiders on file
16
since
$75 K-$733$0Jan 2025: bought $8 K (1 trades), sold $0 (0 trades)Jan 25Jul 2025: bought $75 K (3 trades), sold $0 (0 trades)JulDec 2025: bought $0 (0 trades), sold $733 (1 trades)DecMay 2026: bought $25 K (2 trades), sold $0 (0 trades)May
Bought (open market)Sold (open market)Hover a month for the totals
Cellectar Biosciences, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Jarrod LongcorChief Operating OfficerBuy+8,680$2.880—20,451Form 4
filed James V. CarusoChief Executive Officer, DirectorBuy+8,680$2.880$25 K20,318Form 4
filed John NeisDirectorSellindirect-198$3.700$73310Form 4
filed Chad J. KoleanChief Financial OfficerBuy+5,000$4.990$25 K6,418Form 4
filed Jarrod LongcorChief Operating OfficerBuy+10,000$4.990$50 K12,768Form 4
filed James V. CarusoChief Executive Officer, DirectorBuy+10,000$4.990—11,638Form 4
filed Jarrod LongcorChief Operating OfficerBuy+30,000$0.280$8 K83,141Form 4
filed Jarrod LongcorChief Operating OfficerGrant or award+42,927——53,141Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Cellectar Biosciences, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
218,774
5.2% of shares · 1.65 days to cover
Buybacks, Q1 2014
$0M
Q1 2014
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-30.3 reverse split ; 1-for-10 reverse split

Cellectar Biosciences, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q1 2014Q1 2014$0M
Q4 2013Q4 2013$0M
Q3 2013Q3 2013$0M
Q2 2013Q2 2013$0M
Q1 2013Q1 2013$0M
Q4 2012Q4 2012$0M
Q3 2012Q3 2012$0M
Q2 2012Q2 2012$0M
Q1 2012Q1 2013$0M
Q4 2011Q4 2012$0M
Q3 2011Q3 2011$0M

Trading halts

  • 2025-06-23 23:50 UTC, code T3, resumed 13:00 UTC
  • 2024-12-10 21:55 UTC, code T3, resumed 22:30 UTC

Fails to deliver

  • : 1,190 shares at $1.22
  • : 45,368 shares at $1.24
  • : 45,368 shares at $1.21
  • : 53,170 shares at $1.21
  • : 27,540 shares at $1.22

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Cellectar Biosciences, Inc. scorecard#

Passes 2 of the 12 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.4×Price to book 1.4× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-188.8%Free cash flow is -188.8% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-8.35 vs -41.89Diluted EPS -8.35 in fiscal 2025 against -41.89 the year before (report's currency).
    • ✗Net income higher than five years earlier-$22 M-$22 M in fiscal 2025 against -$15 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$22 MNet income -$22 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-190.9%-190.9% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities3.0×Current ratio 2.96 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year110.7%Diluted shares up 110.7% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Cellectar Biosciences, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Cellectar Biosciences, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Research and development112627r18r18109.06.89.54.8
General and administrative112612r11r6.55.15.24.84.14.7
Total costs and expenses2352392924151413149.4
Operating income−23−52−39−29−24−15−14−13−14−9.4
Other non-operating income (expense)1.27.3−3.9r−3.0r0.00.20.10.10.03.3
Income before tax−22−45−43r−32r−24—————
Income tax—0.1−0.1−0.1——0000
Net income attributable to shareholders−22−45−43r−32r−24−15−14−13−14−6.2
Earnings per share, basic-8.35-36.52r-3.50r-4.51r-4.35r-0.76-1.84-5.23-10.70r-2.14r
Earnings per share, diluted-8.35-41.89r-3.50r-4.51r-4.35r-1.84r-1.84-5.23-10.70r-2.14r
Shares, weighted average (basic)2.61.2r127.15.6r20————
Shares, weighted average (diluted)2.61.2r127.15.6r207.73.01.4r4.4r
Balance sheet
Cash and cash equivalents13239.620365711131011
Other current assets0.81.00.90.70.90.80.80.60.4r0.7
Current assets142410213758111410r12
Property, plant and equipment0.50.81.10.40.30.40.40.50.21.4
Right-of-use (leased) assets0.40.40.50.60.20.30.30——
Goodwill——————001.71.7
Long-term investments——0.00.10.10.10.10.50.5—
Total assets15251222375912151315
Accounts payable1.44.1r5.6r2.6r1.4r1.4r1.3r0.6r0.9r1.4
Current liabilities4.79.425r12r4.03.62.81.62.11.6
Lease liabilities (non-current)0.30.40.50.60.20.30.40——
Non-current liabilities—————0.30.40.20.00.2
Total liabilities5.19.826r12r4.23.93.21.82.11.8
Retained earnings−269−247−203r−160r−151−127−112−98−84−71
Shareholders' equity8.514−15r8.2r29r559.1131114
Total liabilities and equity15251222375912151315
Shares outstanding4.21.5r219.46.1r459.44.71.7r10r
Cash-flow statement
Depreciation and amortization0.20.30.20.10.10.10.10.11.50.4
Share-based compensation2.34.32.41.51.10.50.90.70.80.5
Cash from operating activities−23−48−32−25−23−14−12−11−11−8.3
Capital expenditure−0.0−0.1−0.9−0.2−0.1−0.1−0.0−0.4−0.3−0.1
Cash from investing activities−0.0−0.1−0.9−0.2−0.1−0.1−0.0−0.3−0.3−0.1
Debt issued—————0.2————
Debt repaid———————0−0.1−0.2
Shares issued———9.60.0609.09.14.912r
Cash from financing activities1361239.61.2619.0159.916
Change in cash−1014−10−16−2147−2.73.2−1.47.6
Report10-K10-K10-K10-K/A10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Cellectar Biosciences, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$1.1 M
James V. Caruso
Other top executives, average
$694 K
the CEO earned 1.5× this
$100 invested is now
$6
Cellectar Biosciences, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025James V. Caruso$1.1 M$887 K$694 K$6
2024James V. Caruso$3.0 M$1.3 M$1.5 M$18
2023James V. Caruso$2.0 M$2.4 M$1.2 M$162

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Cellectar Biosciences, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Directors and officers 3 · Material agreement 3 · Unregistered share sale 3 · Shareholder rights changed 3 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 9

Cellectar Biosciences, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Directors and officersShareholder vote8-K
Directors and officers8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Results announced8-K
Material agreementUnregistered share saleShareholder rights changedResults announced8-K
Results announced8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Shareholder vote8-K
Material agreementUnregistered share saleShareholder rights changed8-K
Results announced8-K
Directors and officersBylaws or fiscal year changed8-K
Results announced8-K
Delisting notice8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

3 private funding rounds before listing

Private share sales · funding history

Private share sales of Cellectar Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2023$25 MPrivate placement after listing$10 to $50 million21equity, optionsSEC
Dec 2020$21 MPrivate placement after listing$10 to $50 million16equitySEC
May 2019$5 MPrivate placement after listing$2 to $10 million11equity, optionsSEC
Oct 2017$8 MPrivate placement after listing$2 to $10 million3equity, optionsSEC
Apr 2011$5 MIssued in a merger or acquisition$2 to $10 million—equity, optionsSEC
Aug 2009$4 MNo. 3$2 to $10 million1equity, optionsSEC
Aug 2009$9 MNo. 2$2 to $10 million1equity, optionsSEC
Feb 2009$32 MNo. 1$10 to $50 million12equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at Cellectar Biosciences, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2018–2024
Latest
—
2024-12-10
Cellectar Biosciences, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2024············—
2018············—
Cellectar Biosciences, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
60% of workforceRestructuring planSEC 8-K“Under the workforce reduction plan, the Company is reducing its overall workforce by approximately 60%.”Filing
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

How Cellectar Biosciences, Inc. compares in Biotechnology

  • Market cap$12 M · higher than 12% of 726
  • Price / book1.4× · lower than 69% of 534
  • FCF yield-188.8% · higher than 1% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Cellectar Biosciences, Inc.🇺🇸$12 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Cellectar Biosciences, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Cellectar Biosciences, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Cellectar Biosciences, Inc.? Suggest a correction